A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of XXB750 in heart failure patients with reduced or mildly reduced ejection fraction
Event: ESC Congress 2024
Topic: Pharmacotherapy
Session: Smaller trials, trial updates, and other studies on heart failure (1)
